【摘要】 目的了解深圳地区无偿献血人群HCV感染状况,评估血液经EIA筛查抗-HCV后经血传播HCV感染的残余风险。方法采用两种EIA试剂对献血者血液进行抗-HCV筛查,采用核酸检测技术检测EIA检测"合格"标本中HCV RNA,对HCVRNA阳性标本进行荧光定量PCR检测病毒载量,并对PCR扩增产物进行测序和病毒基因亚型分析。结果共筛查1997～2009年期间的献血者254 570人份,发现抗-HCV阳性1401人份,阳性率为0.55%;对2002～2007年期间EIA检测"合格"的113639份献血者血液标本进行NAT检测,检测出1份HCV RNA阳性、抗-HCV阴性的血清转换窗口期感染的献血者血液,HCV残余风险高达1/113 639。结论 EIA筛查后血液安全性有了很好的保障,但由于HCV感染窗口期存在,经血传播HCV残余风险依然处于较高的水平,NAT应用对提高血液安全,降低输血传播HCV残余风险意义重大。更多还原

【Abstract】 Objective To estimate the residual risk of transfusion-transmitted HCV infection in blood do-nations in Shenzhen.Methods The blood samples of donors were tested for HCV antibody by enzyme immunoas-say(EIA).The blood donation of EIA-negative reaction for HCV RNA were tested by MP-NAT.The anti-HCV positive plasmas were further detected for HCV RNA by RT-PCR.The partial genome of HCVE1 and NS5B was sequenced and genotyped.Results Of 254 570 blood donations during 1997-2009,1401 samples with anti-HCV positive were tested.In 113639 serologically negative blood donations,one was positive for HCV RNA,but nega-tive for HCV antibody.The residual risk of transfusion-transmitted HCV infection was 1:113639.Conclusions There exist high residual risk of transfusion-transmitted HCV infection in blood donations in Shenzhen.Nucleic acid amplification test can further enhance the blood safety and decrease the HCV infection risk of transfusion.更多还原